Revenue Breakdown
Composition ()
No data
Revenue Streams
Sotera Health Co (SHC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sterigenics, accounting for 61.9% of total sales, equivalent to $192.84M. Other significant revenue streams include Nordion and Nelson Labs. Understanding this composition is critical for investors evaluating how SHC navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, Sotera Health Co maintains a gross margin of 56.04%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 35.71%, while the net margin is 15.55%. These profitability ratios, combined with a Return on Equity (ROE) of 10.86%, provide a clear picture of how effectively SHC converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SHC competes directly with industry leaders such as IRTC and CELC. With a market capitalization of $5.20B, it holds a significant position in the sector. When comparing efficiency, SHC's gross margin of 56.04% stands against IRTC's 71.09% and CELC's N/A. Such benchmarking helps identify whether Sotera Health Co is trading at a premium or discount relative to its financial performance.
